Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

TANGO2-related metabolic encephalopathy-arrhythmia syndrome unmasked in 22q11.2 deletion syndrome: hemizygous pathogenic variant, complex phenotype modified by two genetic conditions, and implications for proactive crisis prevention: a case report.

BMC pediatrics·2026

Same author

Nestin as a Vascular Marker of Angiogenesis in Non-Melanoma Skin Cancer.

Cancers·2026

Same author

Cross-Reactivity and Cross-Intolerance Among Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Clinical Patterns, COX-1-Mediated Mechanisms, and Implications for COX-2 Inhibitors and Paracetamol.

International journal of molecular sciences·2026

Same author

Delayed-Type Hypersensitivity to <i>Mycobacterium tuberculosis</i> Antigens: The Immunological Mechanism and Potential Therapeutic Strategies-A Systematic Review.

International journal of molecular sciences·2026

Same author

Hypersensitivity Reactions to Benzodiazepines Used for Perioperative Premedication: A Narrative Review.

Pharmaceuticals (Basel, Switzerland)·2026

Same author

Possible Crosstalk Between Small Intestinal Bacterial Overgrowth (SIBO) and Atopic Manifestations-A Short Overview.

International journal of molecular sciences·2026

Search research articles

Related Experiment Video

Updated: Jun 15, 2025

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

IL-22 in Atopic Dermatitis.

Julia Laska¹, Maciej Tota², Julia Łacwik¹

¹Student Research Group of Microbiology and Immunology, Department of Microbiology and Immunology, Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.

|August 28, 2024

Summary

This summary is machine-generated.

Interleukin-22 (IL-22) is a key driver of inflammation in atopic dermatitis (AD), a chronic skin condition. Elevated IL-22 levels correlate with AD severity, impacting skin barrier function and microbial balance.

Keywords:

AD Th22 atopic dermatitis fezakinumab infections interleukin-22 skin barrier wound healing

More Related Videos

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Related Experiment Videos

Last Updated: Jun 15, 2025

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Area of Science:

Immunology
Dermatology
Molecular Biology

Background:

Atopic dermatitis (AD) is a widespread, chronic inflammatory skin disease with complex causes and varied symptoms.
Current treatments for AD often have limited effectiveness, highlighting the need for novel therapeutic strategies.
Recent research has uncovered new potential drug targets by exploring the disease's underlying mechanisms.

Purpose of the Study:

To review current data on the relationship between Interleukin-22 (IL-22) and atopic dermatitis (AD).
To explore IL-22 as a critical factor in the inflammatory processes of AD.
To identify potential therapeutic targets based on IL-22's role in AD pathogenesis.

Main Methods:

Literature review of recent studies on IL-22 and AD.
Analysis of data correlating IL-22 levels with AD severity.
Examination of IL-22's impact on keratinocyte proliferation, skin microbiota, and epidermal barrier function.

Main Results:

Circulating IL-22 levels are positively correlated with the severity of atopic dermatitis.
Elevated IL-22 contributes to increased keratinocyte proliferation in AD patients.
IL-22 is associated with altered skin microbiota and impaired epidermal barrier function in AD.

Conclusions:

IL-22 plays a significant role in driving the inflammatory response and characteristic symptoms of atopic dermatitis.
Targeting IL-22 presents a promising therapeutic avenue for managing AD.
Understanding the IL-22 pathway is crucial for developing more effective AD treatments.